Baker Bros. Advisors WHWK Position
Exited5-Fund ConvergenceBaker Bros. Advisors exited their position in Whitehawk Therapeutics, Inc. (WHWK) in Q1 2024, after holding the stock for 5 quarters.
The position was first reported in Q1 2023 and has been tracked across 5 quarterly 13F filings.
WHWK is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Full company profile →Short Interest
2.0%
4.3 days to cover
Baker Bros. Advisors WHWK Position History
Frequently Asked Questions
Does Baker Bros. Advisors own WHWK?
No. Baker Bros. Advisors exited their position in Whitehawk Therapeutics, Inc. (WHWK) in Q1 2024. They previously held the stock for 5 quarters.
How many hedge funds own WHWK?
5 specialist biotech hedge funds currently hold WHWK, including Avoro Capital Advisors, OrbiMed Advisors, RA Capital Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy WHWK?
Baker Bros. Advisors's position in WHWK was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's WHWK position increasing or decreasing?
Baker Bros. Advisors completely exited their WHWK position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
WHWKCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →